Scopoletin as a cardioprotective agent against cisplatin-induced oxidative stress and inflammation

Q3 Pharmacology, Toxicology and Pharmaceutics

Phytomedicine Plus Pub Date : 2025-02-01 DOI:10.1016/j.phyplu.2025.100738

Esam Qnais , Omar Gammoh , Yousra Bsieso , Mohammad Alqudah , Mohammad Wedyan , Sara Altaber , Alaa A.A. Aljabali , Abdelrahim Alqudah , Taher Hatahet

{"title":"Scopoletin as a cardioprotective agent against cisplatin-induced oxidative stress and inflammation","authors":"Esam Qnais , Omar Gammoh , Yousra Bsieso , Mohammad Alqudah , Mohammad Wedyan , Sara Altaber , Alaa A.A. Aljabali , Abdelrahim Alqudah , Taher Hatahet","doi":"10.1016/j.phyplu.2025.100738","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cisplatin (CP) is a chemotherapeutic agent notorious for its cardiotoxic effects. Scopoletin, a natural coumarin, has shown potential due to its antioxidant, anti-inflammatory, and anti-apoptotic properties, which may counteract CP-induced cardiotoxicity.</div></div><div><h3>Purpose</h3><div>The study aimed to explore the cardioprotective effects of scopoletin against CP-induced damage in mice, focusing on histopathological changes, cardiac biomarkers, oxidative stress, inflammation, apoptosis, and the modulation of key signaling pathways.</div></div><div><h3>Study Design</h3><div>A controlled experimental design was employed to evaluate scopoletin's efficacy in alleviating CP-induced cardiotoxicity, with dosing variations to assess dose dependency.</div></div><div><h3>Methods</h3><div>Male mice were allocated into five groups: a control group, a cisplatin-only group, two groups treated with low (50 mg/kg/day) and high doses (150 mg/kg/day) of scopoletin in conjunction with cisplatin, and a scopoletin-only group. The interventions were administered over a period of one week, with cardiac damage assessed through histopathological examinations, serum cardiac biomarker measurements, and analyses of oxidative stress, inflammatory cytokines, and apoptosis-related proteins. The efficacy of scopoletin in modulating the p62/Keap1/Nrf2 pathway was also examined.</div></div><div><h3>Results</h3><div>Histopathological assessments showed less tissue damage in scopoletin-treated groups (<em>p</em> < 0.01). Cardiac biomarkers were significantly lower in <span>l</span>- and H-scopoletin groups compared to the CP-only group (<em>p</em> < 0.05, <em>p</em> < 0.01). Scopoletin effectively reduced ROS and MDA levels while enhancing antioxidant enzymes like SOD, CAT, and GSH (<em>p</em> < 0.01). With scopoletin treatment, inflammatory cytokines TNF-α and IL-6 were notably reduced (<em>p</em> < 0.01). Apoptosis analysis revealed lower levels of pro-apoptotic proteins and higher levels of Bcl-2 in scopoletin groups (<em>p</em> < 0.05, <em>p</em> < 0.01). Significantly, scopoletin restored the function of the p62/Keap1/Nrf2 signaling pathway (<em>p</em> < 0.01).</div></div><div><h3>Conclusion</h3><div>The findings suggest scopoletin's potential as an adjunctive therapy in cancer treatment to mitigate CP's adverse effects, warranting further clinical investigation.</div></div>","PeriodicalId":34599,"journal":{"name":"Phytomedicine Plus","volume":"5 1","pages":"Article 100738"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytomedicine Plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667031325000119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cisplatin (CP) is a chemotherapeutic agent notorious for its cardiotoxic effects. Scopoletin, a natural coumarin, has shown potential due to its antioxidant, anti-inflammatory, and anti-apoptotic properties, which may counteract CP-induced cardiotoxicity.

Purpose

The study aimed to explore the cardioprotective effects of scopoletin against CP-induced damage in mice, focusing on histopathological changes, cardiac biomarkers, oxidative stress, inflammation, apoptosis, and the modulation of key signaling pathways.

Study Design

A controlled experimental design was employed to evaluate scopoletin's efficacy in alleviating CP-induced cardiotoxicity, with dosing variations to assess dose dependency.

Methods

Male mice were allocated into five groups: a control group, a cisplatin-only group, two groups treated with low (50 mg/kg/day) and high doses (150 mg/kg/day) of scopoletin in conjunction with cisplatin, and a scopoletin-only group. The interventions were administered over a period of one week, with cardiac damage assessed through histopathological examinations, serum cardiac biomarker measurements, and analyses of oxidative stress, inflammatory cytokines, and apoptosis-related proteins. The efficacy of scopoletin in modulating the p62/Keap1/Nrf2 pathway was also examined.

Results

Histopathological assessments showed less tissue damage in scopoletin-treated groups (p < 0.01). Cardiac biomarkers were significantly lower in l- and H-scopoletin groups compared to the CP-only group (p < 0.05, p < 0.01). Scopoletin effectively reduced ROS and MDA levels while enhancing antioxidant enzymes like SOD, CAT, and GSH (p < 0.01). With scopoletin treatment, inflammatory cytokines TNF-α and IL-6 were notably reduced (p < 0.01). Apoptosis analysis revealed lower levels of pro-apoptotic proteins and higher levels of Bcl-2 in scopoletin groups (p < 0.05, p < 0.01). Significantly, scopoletin restored the function of the p62/Keap1/Nrf2 signaling pathway (p < 0.01).

Conclusion

The findings suggest scopoletin's potential as an adjunctive therapy in cancer treatment to mitigate CP's adverse effects, warranting further clinical investigation.

Abstract Image